AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01854801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual medical Care
Description: Individual medical care in occupational and environmental diseases centers
Study NCT01854801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual electromagnetic exposures
Description: During 7 days, patient hold a dosimeter measuring their electromagnetic exposures for FM, TV, GSM, DECT, WIFI, TETRA and relay antenna emissions. During this week, patients notify intensity and time of their symptoms on a self-questionary
Study NCT03797573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: tDCS will be applied during 20 minutes with a current of 1 mA preceded and followed by a behavioral assessments (Modified Ashworth Scale and Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3 and F4 and the cathodes over C3 and C4.
Study NCT03797573 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Indentical to the active tDCS, except that the stimulation is terminated after 5 seconds.
Study NCT00542958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK012
Description: 9.0, 12.0, 16.0, 21.0, 28.0 mg/m\^2, and to be determined. Intravenous infusion
Study NCT02476500 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LLETZ on a training model
Description: LLETZ is performed on a sausage-based training model using all surgical devices used in the original procedure
Study NCT02476500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LLETZ on a training model
Description: LLETZ is performed on a sausage-based training model using all surgical devices used in the original procedure
Study NCT02677402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion
Study NCT03821688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SAS-JB
Description: single anastomosis sleeve jejunal bypass
Study NCT03821688 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OAGB
Description: one anastomosis gastric bypass
Study NCT03821688 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LSG
Description: laproscopic sleeve gastrectomy
Study NCT02494947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high intensity interval-based aerobic exercise
Description: Interval exercises done 3 times weekly during 6 months according to standard procedures at the Department of Circulation and Medical Imaging.
Study NCT02494947 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Study NCT02494947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Study NCT00429091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-894
Description: Subjects will take 1 mg QD, 2 mg QD, 4 mg QD, 4 mg BID for up to four weeks.
Study NCT00429091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atomoxetine
Description: Subjects will take 40 mg BID or placebo for up to four weeks.
Study NCT00429091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will take BID for up to four weeks
Study NCT06479746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional support
Description: Emotional support helps the woman giving birth effectively, meets her emotional needs and expectations, ensures her comfort, improves birth outcomes, increases her self-esteem, ensures a positive birth experience and facilitates her transition into the role of motherhood.
Study NCT02148731 — intervention group
Intervention type: OTHER
Intervention: Frailty markers
Description: Brief screening assessment, CGA and frailty markers will be evaluate at inclusion. CGA and frailty markers will be evaluated at 3, 6, 12 and 18 months after the beginning of chemotherapy. Criteria for toxicity and adverse outcomes will be recorded at each cycle or visits
Study NCT02406742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: CC-122 will be administered daily starting at Cycle 1 Day 1 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.
Study NCT02406742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study NCT02406742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered as an intravenous (IV) infusion at a dose of 100 mg on Cycle 1 Day 1 and 900 mg on Cycle 1 Day 2 and 1000 mg on Cycle 1 Days 8 and 15. The dose of obinutuzumab on Days 1 and 2 of Cycle 1 may be adjusted per institutional practice as long as the combined dose equals 1000 mg. Obinutuzumab will be administered at a dose of 1000 mg on Day 1 of Cycles 2 through 6.
Study NCT01031134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Decision Making
Description: Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.
Study NCT01031134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care reflects the standard of care in primary care practice: following physician recommendation for treatment. Physicians will recommend some form of depression treatment. This may take the form of an antidepressant prescription or psychotherapy referral. The physician will encourage patients to telephone with any questions. Following the treatment recommendation provided to the patient, the physician will provide care as usual.
Study NCT02493985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.5% CO2
Description: The subjects will be randomized to breath 0.5% carbon dioxide during one of the -12 degree head down tilt body position periods in crossover design
Study NCT02493985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ambient air
Description: The subjects will be randomized to breath ambient air during one of the -12 degree head down tilt body position periods in crossover design
Study NCT01031342 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early colonoscopy
Description: Colonoscopy within 12 hours of presentation
Study NCT01031342 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective colonoscopy
Description: Colonoscopy 36-60 hours after presentation
Study NCT03072329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block
Study NCT03072329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study NCT00602979 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Macintosh laryngoscope
Description: Used during laryngoscopy to facilitate intubation.
Study NCT00602979 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Airtraq® Optical Laryngoscope
Description: Used during laryngoscopy to facilitate intubation.
Study NCT00602979 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Storz DCI Video Laryngoscope®
Description: Used during laryngoscopy to facilitate intubation
Study NCT00602979 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GlideScope® Video Laryngoscope
Description: Used during laryngoscopy to facilitate intubation
Study NCT00602979 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: McGRATH® Video Laryngoscope
Description: Used during laryngoscopy to facilitate intubation
Study NCT00995488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007 (Abraxane®)
Description: ABI-007 is a novel albumin-bound paclitaxel combining a protein with a chemotherapeutic agent in the particle form.
Study NCT01700972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myocardial perfusion imaging
Description: The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging. The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
Study NCT04024670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arts Intervention
Description: If selected for the arts activity, an artist in residence will visit you 3 times a week for a total of 3 weeks during your hospital stay. Two visits will focus on the arts activity and one visit will be the administration of the questionnaire. Each visit will be approximately 25 minutes at a time.
Study NCT00856193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules were supplied for inhalation once daily with Concept 1 device.
Study NCT00856193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules were supplied for inhalation once daily with Concept 1 device.
Study NCT00856193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 50 μg capsules were supplied for inhalation once daily with Concept 1 device.
Study NCT00856193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NVA237
Description: NVA237 50 μg capsules were supplied for inhalation once daily with Concept 1 device.
Study NCT01063192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Arm 1: Gemcitabine alone on D1,8,15 every 28 days for 3 cycles
Study NCT01063192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, Oxaliplatin, 5-Fluorouracil, Leucovorin (GOFL)
Description: Arm 2: GOFL on D1, 15 every 28 days for 3 cycles(Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
Study NCT02123004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 180mg loading dose for one day ,and then 90mg per day for 4 weeks
Study NCT02123004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 300mg loading dose for one day ,and then 75mg per day for 4 weeks
Study NCT04364035 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo delivered as one 0. 5 mL IM injection
Study NCT04364035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Unit-dose placebo tablet delivered as two 3-mg placebo tablets
Study NCT01483131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 12 weeks of resistance training twice a week.
Study NCT02871154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delaying oocyte pick up beyond 39 hours post hCG
Description: Unlike the traditional less-than 39 hours interval from hCG injection to oocyte pick up, we will extend the interval up to 47 hours
Study NCT03691454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 50mg/m2, intravenous drip, D1, combined with Oxaliplatin 85mg/m2，intravenous drip 2h，D1 and S-1 40-60mg bid(BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid)，D1-7；For patients with Her2 positive, add Herceptin 4mg/kg(6mg/kg first cycle) D1; every 14 days for a cycle.
Study NCT03691454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2，intravenous drip 2h，D1 combined with S-1 40-60mg bid(BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid)，D1-14；For patients with Her2 positive, add Herceptin 6mg/kg(8mg/kg first cycle) D1; every 21 days for a cycle.
Study NCT05169801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP102, paclitaxel, carboplatin
Description: BP102, paclitaxel, carboplatin
Study NCT05169801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin®, paclitaxel, carboplatin
Description: Avastin®, paclitaxel, carboplatin
Study NCT01876121 — intervention group
Intervention type: DRUG
Intervention: Celecoxib
Description: oral
Study NCT02334878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cells,Mesenchymal
Description: The patient will be placed in lithotomy position. A Foley's catheter (size 18) will be inserted in the urethra, then under local anaesthesia; retrieved cells (total 20- 30 million cells per patient in 10cc syringe) will be injected into the submucosal tissue at the level of the proximal urethra just distal to the bladder neck (guided by stretch on the Foley's catheter), at 3,9,12 o'clock, injecting around 3.5 cc in each site.
Study NCT02334878 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery (TVT)
Description: A small midurethral incision will be made in the vaginal mucosa, then a polypropylene 40\*1cm mesh tape attached to two curved trocars will be passed lateral to the urethra \& through the endopelvic fascia into the retropubic space. The trocar will then be passed along the back of the pubic bone, through the rectus fascia, in two small suprapubic skin incisions, then the tension on the tape adjusted \& the remaining tape cut off at the level of the skin.
Study NCT02615782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-397
Description: CKD-397 1T single oral administration under fasting condition or fed condition(high fat meals)
Study NCT04186793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Grocery Shopping (GGS)
Description: The GGS group will be scheduled for 4 weekly sessions to co-shop with the study Registered Dietitian (RD) or clinical research coordinator (CRC). The primary shopper for the household will be required to attend all 4 sessions. The study participant will be required to attend at least 1 session and other family/household members will be encouraged to attend. The weekly sessions will take place at the family's primary grocery store. During each session, the RD will facilitate selection of low free sugar foods and guide the primary shopper on menu planning for a low free sugar diet. In the 4th session, the primary shopper will be asked to shop independently while being observed by the RD/CRC. Prior to checking out, the RD/CRC will approve and/or correct their shopping choices.~During the follow-up period, all participants will receive diet counseling/support calls from the dietitian and/or research team at Months 2, 4, and 6, following intervention completion.
Study NCT04186793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Provision Group
Description: This intervention will be applied to each family and will target foods and beverages that contain free sugars added to food by consumer, cook, or manufacturer, but preserve the family's other food group choices. During the 4 week long intervention, families will be able to choose meals from a list of foods similar to their usual diet. Groceries for each week will be delivered to the family. Each child will be provided with a lunch bag and instructed to bring lunch to school to maintain the study diet.~Families will have the opportunity to choose from a list of pre-prepared evening meals that are similar to what they consumed before study initiation but without free sugars. The families will be instructed to not eat any food outside of the assigned diet.~During the follow-up period, all participants will receive diet counseling/support calls from the dietitian and/or research team at Months 2, 4, and 6, following intervention completion.
Study NCT03082339 — intervention group
Intervention type: OTHER
Intervention: Cortisone
Description: Observation of QTc-interval
Study NCT03175640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation intervention
Description: The implementation intervention includes peer-to-peer training, post-training outreach, proactive expert support, and assistance with addressing environmental barriers.
Study NCT01483131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training with vascular occlusion
Description: 12 weeks of resistance training with vascular occlusion twice a week
Study NCT00123240 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie high carbohydrate diet
Description: 65% carbohydrate, 15% protein, 20% fat (7% SFA, 8% MFA, 4% PUFA), P/S 0.63, 152 mg cholesterol/1500 kcal
Study NCT00123240 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie high fat/protein diet
Description: High Fat/Protein Diet: 10% carbohydrate, 25% protein, 65% fat (26% SFA, 25% MFA, 9% PUFA), P/S 0.33, 458 mg cholesterol/1500 kcal
Study NCT02642913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study NCT02642913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide with Sorafenib
Study NCT02782819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic crystalloid solution resuscitation
Description: Patient will receive normal saline or Ringer lactate or other balance salt solution during fluid resuscitation for shock reversal.
Study NCT02782819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic crystalloid solution resuscitation
Description: Patient will receive normal saline or Ringer lactate or other balance salt solution during fluid resuscitation for shock reversal.
Study NCT02782819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloid solution resuscitation
Description: Patient will receive 5% albumin or gelatin solution during shock resuscitation
Study NCT01639209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy
Description: Pars plana vitrectomy plus laser/cryotherapy
Study NCT01639209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumatic retinopexy
Description: Pneumatic retinopexy plus laser/cryotherapy
Study NCT02619045 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telephone follow-up nursing device
Description: Telephone follow-up nursing device involving:~* telephone appointments made by a dedicated nurse and set up at key stage of treatment (1 phone call per week during chemotherapy cycles),~* specific questionnaire used by the nurse at each phone call (toxicity, general care, quality of life...),~* actions taken for the patient following each phone call (consultation with a doctor, patient hospitalization, sending of a prescription, coordination with the city medical caregiver);
Study NCT02588118 — intervention group
Intervention type: DRUG
Intervention: propofol
Description: Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
Study NCT01586494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ULTRAM ER
Description: One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
Study NCT01586494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ULTRAM ER
Description: The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
Study NCT02588118 — intervention group
Intervention type: DRUG
Intervention: Cisatracurium
Description: Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
Study NCT02349711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Description: A 350 mg capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
Study NCT02349711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Supplement contains 348.25 mg of potato starch.
Study NCT04432818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pack Health's digital life coaching (DLC)
Description: Pack Health smartphone-based DLC platform will be provided for 16-week subscription which allows unlimited bidirectional communication between enrolled participants and their life coach
Study NCT04723173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feature for noise reduction (on)
Description: The noise reduction feature shall support the hearing aid user in noisy situations and shall reduce the listening effort.
Study NCT04723173 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Feature for noise reduction (off)
Description: To show the advantage of the noise reduction feature there is a comparison without the feature necessary.
Study NCT03500796 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Platelet rich plasma clot implantation
Description: Implantation of a platelet rich plasma clot, which is created from the plasma of the patients, and refrigerated to be inserted under the sealing amniotic membrane